[go: up one dir, main page]

FI3656869T4 - Kantasolujen siirrostaminen kantasoluihin kohdentuvan aineen ja immunoregulatorista signaalia moduloivan aineen yhdistelmän kanssa - Google Patents

Kantasolujen siirrostaminen kantasoluihin kohdentuvan aineen ja immunoregulatorista signaalia moduloivan aineen yhdistelmän kanssa Download PDF

Info

Publication number
FI3656869T4
FI3656869T4 FIEP19198976.3T FI19198976T FI3656869T4 FI 3656869 T4 FI3656869 T4 FI 3656869T4 FI 19198976 T FI19198976 T FI 19198976T FI 3656869 T4 FI3656869 T4 FI 3656869T4
Authority
FI
Finland
Prior art keywords
agent
use according
stem cells
sirpα
human patient
Prior art date
Application number
FIEP19198976.3T
Other languages
English (en)
Swedish (sv)
Inventor
Judith Shizuru
Kipp Andrew Weiskopf
Aaron Michael Ring
Akanksha Chhabra
Peter Schnorr
Irving L Weissman
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55400510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI3656869(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of FI3656869T4 publication Critical patent/FI3656869T4/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Oncology (AREA)

Claims (11)

EP3656869 1 Patenttivaatimukset
1. Aine, joka estää CD47:n ja SIRPa:n välisen interaktion, käytettäväksi menetelmässä hematopoieettisen kantasolun siirrostamiseksi ihmispotilaaseen, joka kärsii geneettisestä verisairaudesta, jossa menetelmä käsittää: — mainitun ihmispotilaan saattamisen kosketukseen samanaikaisesti: (i) aineen kanssa, joka spesifisesti sitoutuu endogeenisiin hematopoieettisiin kantasoluihin luuytimessä, jossa aine on monoklonaalinen vasta-aine, joka on spesifinen CD117:lle, ja (ii) aineen kanssa, joka estää CD47:n ja SIRPa:n välisen interaktion, jossa aine on — valittu anti-CD47-vasta-aineesta, liukoisesta SIRPa-polypeptidistä tai SIRPa- polypeptidiä käsittävästä fuusioproteiinista; annoksella, joka tehokkaasti poistaa kohdennettuja endogeenisia hematopoieettisia kantasoluja mainitusta ihmispotilaasta; ja eksogeenisten normaalin fenotyypin omaavien hematopoieettisten kantasolujen antamisen mainitulle ihmispotilaalle.
2. Aine käytettäväksi patenttivaatimuksen 1 mukaisesti, jossa geneettinen verisairaus on aplastinen anemia.
3. Aine käytettäväksi patenttivaatimuksen 1 mukaisesti, jossa geneettinen verisairaus on sirppisolutauti.
4 Aine käytettäväksi patenttivaatimuksen 1 mukaisesti, jossa geneettinen verisairaus on talassemia.
5. Aine käytettäväksi jonkin patenttivaatimuksen 1 - 4 mukaisesti, jossa siirrostaminen suoritetaan ilman myoablatiivista valmisteluhoitoa.
6. Aine käytettäväksi patenttivaatimuksen 1 tai patenttivaatimuksen 5, kun se on — riippuvainen — patenttivaatimuksesta 1, mukaisesti jossa ihmispotilas on immunokompetentti.
EP3656869
2
7. Aine käytettäväksi jonkin patenttivaatimuksen 1 - 6 mukaisesti, jossa mainitut eksogeeniset kantasolut ovat allogeenisia kantasoluja.
8. Aine käytettäväksi jonkin patenttivaatimuksen 1 - 6 mukaisesti, jossa eksogeeniset kantasolut ovat geneettisesti modifioituja autologisia kantasoluja.
9. Aine käytettäväksi jonkin patenttivaatimuksen 1 - 8 mukaisesti, jossa aine, joka estää CD47:n ja SIRPa:n välisen interaktion, on anti-CD47-vasta-aine .
10. Aine käytettäväksi patenttivaatimuksen 9 mukaisesti, jossa vasta-aine on bispesifinen vasta-aine.
11. Aine käytettäväksi jonkin patenttivaatimuksen 1 - 8 mukaisesti, jossa aine, joka estää CD47:n ja SIRPa:n välisen interaktion, on liukoinen SIRPa-polypeptidi tai SIRPa-polypeptidiä käsittävä fuusioproteiini.
FIEP19198976.3T 2014-08-26 2015-08-26 Kantasolujen siirrostaminen kantasoluihin kohdentuvan aineen ja immunoregulatorista signaalia moduloivan aineen yhdistelmän kanssa FI3656869T4 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462041989P 2014-08-26 2014-08-26

Publications (1)

Publication Number Publication Date
FI3656869T4 true FI3656869T4 (fi) 2025-06-04

Family

ID=55400510

Family Applications (2)

Application Number Title Priority Date Filing Date
FIEP19198976.3T FI3656869T4 (fi) 2014-08-26 2015-08-26 Kantasolujen siirrostaminen kantasoluihin kohdentuvan aineen ja immunoregulatorista signaalia moduloivan aineen yhdistelmän kanssa
FIEP15835482.9T FI3186395T4 (fi) 2014-08-26 2015-08-26 Kantasolujen siirto kantasoluihin kohdistuvan aineen ja immunoregulatorisen signaloinnin modulaation yhdistelmällä

Family Applications After (1)

Application Number Title Priority Date Filing Date
FIEP15835482.9T FI3186395T4 (fi) 2014-08-26 2015-08-26 Kantasolujen siirto kantasoluihin kohdistuvan aineen ja immunoregulatorisen signaloinnin modulaation yhdistelmällä

Country Status (14)

Country Link
US (4) US10406179B2 (fi)
EP (4) EP3656869B2 (fi)
CA (2) CA3229961A1 (fi)
CY (1) CY1123730T1 (fi)
DK (2) DK3186395T4 (fi)
ES (3) ES2845898T5 (fi)
FI (2) FI3656869T4 (fi)
HR (1) HRP20210057T4 (fi)
HU (2) HUE046387T2 (fi)
LT (1) LT3656869T (fi)
PL (2) PL3186395T5 (fi)
PT (2) PT3186395T (fi)
SI (1) SI3656869T2 (fi)
WO (1) WO2016033201A1 (fi)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013209736C1 (en) * 2012-01-17 2017-12-14 The Board Of Trustees Of The Leland Stanford Junior University High affinity SIRP-alpha reagents
SI3656869T2 (sl) 2014-08-26 2025-06-30 The Board Of Trustees Of The Leland Stanford Junior University Vsaditev matičnih celic s kombinacijo sredstva, ki cilja matične celice in modulacija imunoregulatornega signaliziranja
US10550187B2 (en) * 2014-10-24 2020-02-04 Incept, Llc Extra luminal scaffold
WO2016164502A1 (en) 2015-04-06 2016-10-13 President And Fellows Of Harvard College Compositions and methods for non-myeloablative conditioning
SG10202101909RA (en) 2015-08-07 2021-04-29 Alx Oncology Inc Constructs having a sirp-alpha domain or variant thereof
SI3341015T2 (sl) 2015-08-26 2024-03-29 The Board Of Trustees Of The Leland Stanford, Junior University Izboljšana deplecija ciljanih celic z blokado CD47 in imunostimulatornim agonistom
CN109661400A (zh) * 2016-06-17 2019-04-19 美真达治疗公司 用于耗尽cd117+细胞的组合物和方法
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
CN110461876B (zh) 2017-01-20 2024-05-17 海德堡医药研究有限责任公司 用于耗尽cd137+细胞的组合物和方法
WO2018140940A1 (en) * 2017-01-30 2018-08-02 The Board Of Trustees Of The Leland Stanford Junior University A non-genotoxic conditioning regimen for stem cell transplantation
WO2018165015A1 (en) 2017-03-09 2018-09-13 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pediatric brain tumors with targeting of cd47 pathway
BR112020001679A2 (pt) 2017-08-02 2020-07-21 Phanes Therapeutics, Inc. anticorpos anti-cd47 e usos dos mesmos
CA3078963A1 (en) * 2017-10-25 2019-05-02 Actinium Pharmaceuticals, Inc. Anti-cd45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies
WO2019113437A1 (en) * 2017-12-08 2019-06-13 The Board Of Trustees Of The Leland Stanford Junior University Hematopoietic stem cell engraftment
MA52091A (fr) 2018-03-21 2021-01-27 Alx Oncology Inc Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation
EP3799603A4 (en) 2018-05-11 2022-03-02 Beam Therapeutics, Inc. METHODS OF PATHOGENIC AMINO ACID SUBSTITUTION USING PROGRAMMABLE BASE EDITOR SYSTEMS
EP3801635A4 (en) * 2018-06-07 2022-04-06 Magenta Therapeutics, Inc. THERAPEUTIC METHODS USING ANTIBODY-DRUG CONJUGATE (ADC)
TW202028237A (zh) 2018-09-27 2020-08-01 美商西建公司 SIRPα結合蛋白及其使用方法
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
UA128431C2 (uk) 2018-11-26 2024-07-10 Форті Севен, Інк. ГУМАНІЗОВАНЕ АНТИТІЛО ДО c-Kit
EP3886869A4 (en) 2018-11-28 2022-07-06 Forty Seven, Inc. GENETICALLY MODIFIED ABLATION-RESISTANT HSPCS
JP2022530100A (ja) * 2019-04-25 2022-06-27 アクティニウム ファーマシューティカルズ インコーポレイテッド 悪性および非悪性血液疾患の治療のための免疫枯渇の組成物および方法
CA3140639A1 (en) * 2019-05-24 2020-12-03 Forty Seven, Inc. Regimes for co-administration of immunotherapeutic agents against c-kit and cd47
AU2020282791A1 (en) 2019-05-31 2021-12-09 ALX Oncology Inc. Methods of treating cancer with SIRP alpha Fc fusion in combination with an immune checkpoint inhibitor
US20240000847A1 (en) * 2020-11-06 2024-01-04 Bluebird Bio, Inc. Methods
EP4337190A1 (en) 2021-05-13 2024-03-20 ALX Oncology Inc. Combination therapies for treating cancer
US20250302953A1 (en) 2022-02-14 2025-10-02 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
US20250171536A1 (en) * 2022-03-01 2025-05-29 CSL Innovation Pty Ltd Methods of Bone Marrow Conditioning
WO2023183313A1 (en) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
WO2023183555A1 (en) * 2022-03-25 2023-09-28 Memorial Sloan-Kettering Cancer Center Method of promoting thymic recovery by administering hematopoietic stem cells with low c-kit expression
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
EP4516807A1 (en) 2023-08-28 2025-03-05 Consorcio Centro de Investigación Biomédica en Red Compositions for use in a method of providing improved hematopoietic stem cell engraftment
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686278A (en) * 1994-03-25 1997-11-11 Indiana University Foundation Methods for enhanced retrovirus-mediated gene transfer
IL129222A0 (en) 1996-10-01 2000-02-17 Geron Corp Telomerase reverse transcriptase
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US6638501B1 (en) 1997-09-29 2003-10-28 Neurospheres Holdings Ltd. Use of multipotent neural stem cell progeny to augment non-neural tissues
US5958767A (en) 1998-08-14 1999-09-28 The Children's Medical Center Corp. Engraftable human neural stem cells
WO2001046384A2 (en) 1999-12-23 2001-06-28 Cornell Research Foundation, Inc. A method for isolating and purifying multipotential neural progenitor cells and multipotential neural progenitor cells
WO2004002425A2 (en) * 2002-06-28 2004-01-08 Bio Transplant, Inc. Process for promoting graft acceptance by depletion of hematopoietic stem cells
EP1581056B1 (en) * 2002-12-13 2010-07-21 Genetix Pharmaceuticals Inc. Therapeutic retroviral vectors for gene therapy
US20090191202A1 (en) * 2005-09-29 2009-07-30 Jamieson Catriona Helen M Methods for manipulating phagocytosis mediated by CD47
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
WO2008067115A2 (en) * 2006-11-03 2008-06-05 The Board Of Trustees Of The Leland Stanford Junior University Selective immunodepletion of endogenous stem cell niche for engraftment
JP5547656B2 (ja) * 2008-01-15 2014-07-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Ｃｄ４７によって媒介される食作用を操作するための方法
SI2477648T1 (sl) * 2009-09-15 2022-09-30 The Board Of Trustees Of The Leland Stanford Junior University Sinergijska terapija proti CD47 za krvne rake
CA3138956A1 (en) 2010-05-14 2011-11-17 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to cd47
US20140242095A1 (en) 2011-10-19 2014-08-28 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
AU2013209736C1 (en) 2012-01-17 2017-12-14 The Board Of Trustees Of The Leland Stanford Junior University High affinity SIRP-alpha reagents
JP6606505B2 (ja) 2014-03-11 2019-11-13 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 抗ＳＩＲＰα抗体および二重特異性マクロファージ増強抗体
SI3656869T2 (sl) 2014-08-26 2025-06-30 The Board Of Trustees Of The Leland Stanford Junior University Vsaditev matičnih celic s kombinacijo sredstva, ki cilja matične celice in modulacija imunoregulatornega signaliziranja
US10618976B2 (en) 2015-06-16 2020-04-14 The Board Of Trustees Of The Leland Stanford Junior University SIRP-α agonist antibody

Also Published As

Publication number Publication date
EP3822364B1 (en) 2023-05-10
ES2763248T5 (es) 2023-06-22
EP4257145A3 (en) 2023-10-18
DK3186395T3 (da) 2019-11-25
CA2958884A1 (en) 2016-03-03
US10406179B2 (en) 2019-09-10
HRP20210057T1 (hr) 2021-03-05
ES2845898T3 (es) 2021-07-28
EP3186395B1 (en) 2019-09-25
CA2958884C (en) 2024-02-27
DK3656869T4 (da) 2025-05-19
HRP20210057T4 (hr) 2025-07-18
CA3229961A1 (en) 2016-03-03
SI3656869T2 (sl) 2025-06-30
US20200129557A1 (en) 2020-04-30
EP3656869B1 (en) 2020-11-11
FI3186395T4 (fi) 2023-05-25
EP4257145A2 (en) 2023-10-11
PL3656869T3 (pl) 2021-05-17
EP3186395A4 (en) 2018-03-21
CY1123730T1 (el) 2022-05-27
DK3186395T4 (da) 2023-05-08
EP3186395B2 (en) 2023-03-29
DK3656869T3 (da) 2021-01-04
PL3186395T5 (pl) 2023-06-12
EP3186395A1 (en) 2017-07-05
EP3656869A1 (en) 2020-05-27
PL3656869T5 (pl) 2025-06-09
PL3186395T3 (pl) 2020-02-28
EP3822364A1 (en) 2021-05-19
ES2945588T3 (es) 2023-07-04
US20170224737A1 (en) 2017-08-10
ES2763248T3 (es) 2020-05-27
EP3656869B2 (en) 2025-04-09
EP4257145B1 (en) 2025-06-25
EP3656869A8 (en) 2020-06-10
US12233093B2 (en) 2025-02-25
PT3186395T (pt) 2019-11-20
ES2845898T5 (en) 2025-06-17
US11419897B2 (en) 2022-08-23
HUE046387T2 (hu) 2020-03-30
HUE052725T2 (hu) 2021-05-28
US20220347224A1 (en) 2022-11-03
SI3656869T1 (sl) 2021-03-31
PT3656869T (pt) 2021-01-13
WO2016033201A1 (en) 2016-03-03
US20250249042A1 (en) 2025-08-07
LT3656869T (lt) 2021-01-25

Similar Documents

Publication Publication Date Title
FI3656869T4 (fi) Kantasolujen siirrostaminen kantasoluihin kohdentuvan aineen ja immunoregulatorista signaalia moduloivan aineen yhdistelmän kanssa
Planat-Benard et al. MSCs and inflammatory cells crosstalk in regenerative medicine: concerted actions for optimized resolution driven by energy metabolism
Srivastava et al. Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting
Monsel et al. Mesenchymal stem cell derived secretome and extracellular vesicles for acute lung injury and other inflammatory lung diseases
Abughanam et al. Mesenchymal stem cells extract (MSCsE)-based therapy alleviates xerostomia and keratoconjunctivitis sicca in Sjogren’s syndrome-like disease
MX2024012897A (es) Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer
Paebst et al. Comparative immunophenotyping of equine multipotent mesenchymal stromal cells: an approach toward a standardized definition
Yeo et al. Exosome: a novel and safer therapeutic refinement of mesenchymal stem cell
Mitkari et al. Human bone marrow mesenchymal stem/stromal cells produce efficient localization in the brain and enhanced angiogenesis after intra-arterial delivery in rats with cerebral ischemia, but this is not translated to behavioral recovery
MX2019009720A (es) Metodos y composiciones para la transferencia de genes a traves de la vasculatura.
AR118465A1 (es) Vectores de virus adenoasociados recombinantes
CL2020000810A1 (es) Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas.
Roderfeld et al. Bone marrow transplantation improves hepatic fibrosis in Abcb4−/− mice via Th1 response and matrix metalloproteinase activity
WO2019222275A3 (en) Compositions and methods for tcr reprogramming using inducible fusion proteins
CL2016003096A1 (es) Métodos para cosechar cultivos de células de mamífero
MY201723A (en) Constrained conditionally activated binding proteins
CO6680693A2 (es) Anticuerpos humanos recombinantes, tanto humanizados como quiméricos, los cuales en lazan especificamente a ox40 humano
MX2018006789A (es) Receptores quimericos modificados y composiciones y metodos relacionados.
MX392416B (es) Métodos y composiciones para terapia celular adoptiva.
EA201270571A1 (ru) Человеческие il-23-антигенсвязывающие белки
D’Amario et al. Dystrophin cardiomyopathies: clinical management, molecular pathogenesis and evolution towards precision medicine
EA201290759A1 (ru) Антитела
Ciervo et al. Adipose-derived stem cells protect motor neurons and reduce glial activation in both in vitro and in vivo models of ALS
Hao et al. SDF‐1/CXCR4 Axis Promotes MSCs to Repair Liver Injury Partially Through Trans‐Differentiation and Fusion With Hepatocytes
PH12014502548A1 (en) Method for identifying ligands of the ahr receptor having therapeutic sebosuppressive activity, and said ligands